Drug Profile
LY 3321367
Alternative Names: LY3321367Latest Information Update: 25 Oct 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antibodies; Antineoplastics
- Mechanism of Action HAVCR2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 17 Oct 2023 Eli Lilly and Company completes a phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in the US, Japan, South Korea and Spain (IV) (NCT03099109)
- 28 May 2020 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV)
- 28 May 2020 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (IV)